Inertia
Well-Known Member
I've been following this Pharmaceutical Co. for a few years, waiting to be able to give good news other than CBD related in that thread.
A non-opiod pain reliever .
The Food and Drug Administration is scheduled to make a decision on whether to approve it as a treatment for acute pain in January.
But before year-end, analysts expect to see the results of a suzetrigine study in patients with LSR, or lumbosacral radiculopathy. This condition occurs when nerves in the spine are compressed or irritated. It can cause leg pain known as sciatic pain. If suzetrigine works in LSR, it could provide fodder for approval in chronic pain treatment. Chronic pain is often treated with highly addictive opioids.
A non-opiod pain reliever .
The Food and Drug Administration is scheduled to make a decision on whether to approve it as a treatment for acute pain in January.
But before year-end, analysts expect to see the results of a suzetrigine study in patients with LSR, or lumbosacral radiculopathy. This condition occurs when nerves in the spine are compressed or irritated. It can cause leg pain known as sciatic pain. If suzetrigine works in LSR, it could provide fodder for approval in chronic pain treatment. Chronic pain is often treated with highly addictive opioids.
